NCT07903311
Iron Repletion in Cystic Fibrosis
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Secondary (20)
Show 15 moreShow less
Arms and interventions
Participants enrolled in the ID Cohort will be randomized to an IV versus PO route of iron repletion in a 1:1 ratio. Participants are only randomized by route of repletion, not to a specified drug or dose. Rather, selection of the iron repletion formulation and dose will be determined by the participant's treating clinician. This arm is randomized to the IV route of administration.
Participants enrolled in the ID Cohort will be randomized to an IV versus PO route of iron repletion in a 1:1 ratio. Participants are only randomized by route of repletion, not to a specified drug or dose. Rather, selection of the iron repletion formulation and dose will be determined by the participant's treating clinician. This arm is randomized to the PO route of administration.
Participants enrolled in the Borderline ID Cohort will be randomized to a PO route of iron repletion versus usual care without specific assignment of iron repletion in a 1:1 ratio. Participants are not randomized to a specific drug or dose. Rather, selection of the iron repletion formulation and dose will be determined by the participant's treating clinician. This arm is randomized to the PO route of administration.
Participants enrolled in the Borderline ID Cohort will be randomized to a PO route of iron repletion versus usual care without specific assignment of iron repletion in a 1:1 ratio. Usual care is defined as continued clinical care as usual without a specific plan to replete iron. This arm is randomized to usual care.
Drugs: IV Repletion, PO Repletion
Sites
8 sites in 1 country